Use access key #2 to skip to page content.
$0.25 0.01 (4.17%)
10/7/2008 3:45 PM

Panacos Pharmaceuticals, Inc. (PANC)

CAPS Rating:
*****

A development stage biotechnology company that seeks to develop next generation anti-infective products through the discovery and development of small-molecule oral drugs designed to treat HIV and other major human viral diseases.

View All Commentary (PANC)

Recs

4

Avatar Ganndalf (< 20) Submitted: 9/11/07 8:58 AM : Outperform Start Price: $3.95 PANC Score: -63.67

This biotech company could hit it BIG, and I have been an owner of them in the past 12 months. But then they might not. Ha Ha. OK, seriously now, the problem is that Bevirimat showed excellent results when it was tested as a liquid formulation, but then when they put it in a tablet, its bioavailability was quite poor and so it did not perform well at all. For this drug to really do well commercially, it seems, based on my limited experience in biotech, that Bevirimat needs to have a tablet or capsule formulation. This may well happen, but I don't think one should expect it. At this time, my gut feeling is that chances are below 50% that they can find a tablet/capsule formulation for this drug. (But I MIGHT be wrong on this.)

So what is the bottom line? Panacos is very high risk right now, but if it looks like they've come up with a pill formulation that is working well in trials, I would seriously consider buying back into Panacos. It is a company well worth keeping an eye on in my opinion.

Report this Post Replies: 0 | Reply

Featured Broker Partners